deltatrials
Active Not Recruiting PHASE3 INTERVENTIONAL 2-arm NCT02970318

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

A Randomized, Multicenter, Open-Label, Phase 3 Study of Acalabrutinib (ACP-196) Versus Investigator's Choice of Either Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Subjects With R/R Chronic Lymphocytic Leukemia

Sponsor: Acerta Pharma BV

Conditions Chronic Lymphocytic Leukemia
Interventions Acalabrutinib (ACP-196) Bendamustine Idelalisib Rituximab
Updated 25 times since 2017 Last updated: Jan 20, 2026 Started: Feb 2, 2017 Primary completion: Sep 3, 2021 Completion: Oct 1, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Chronic Lymphocytic Leukemia and is currently ongoing. Acerta Pharma BV leads this study, which shows 25 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2017 · 4 months · monthly snapshot~Jun 2017 – ~Jun 2018 · 12 months · monthly snapshot~Jun 2018 – ~Apr 2019 · 10 months · monthly snapshot~Apr 2019 – ~Sep 2019 · 5 months · monthly snapshot~Sep 2019 – ~Jan 2021 · 16 months · monthly snapshot~Jan 2021 – ~Jun 2021 · 5 months · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshot~Dec 2021 – ~Apr 2022 · 4 months · monthly snapshot~Apr 2022 – ~Jul 2022 · 3 months · monthly snapshot~Jul 2022 – ~Jul 2023 · 12 months · monthly snapshot~Jul 2023 – ~Oct 2023 · 3 months · monthly snapshot~Oct 2023 – ~Jan 2024 · 3 months · monthly snapshot~Jan 2024 – ~Apr 2024 · 3 months · monthly snapshot~Apr 2024 – ~Jun 2024 · 2 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Dec 2024 · 3 months · monthly snapshot~Dec 2024 – ~Mar 2025 · 3 months · monthly snapshot~Mar 2025 – ~Sep 2025 · 6 months · monthly snapshot~Sep 2025 – ~Nov 2025 · 2 months · monthly snapshot~Nov 2025 – ~Dec 2025 · 30 days · monthly snapshot~Dec 2025 – ~Feb 2026 · 2 months · monthly snapshot~Feb 2026 – present · 5 months · monthly snapshot

Change History

25 versions recorded

  1. Feb 2026 — Present [monthly]

    Active Not Recruiting PHASE3

  2. Dec 2025 — Feb 2026 [monthly]

    Active Not Recruiting PHASE3

  3. Nov 2025 — Dec 2025 [monthly]

    Active Not Recruiting PHASE3

  4. Sep 2025 — Nov 2025 [monthly]

    Active Not Recruiting PHASE3

  5. Mar 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE3

▶ Show 20 earlier versions

  1. Dec 2024 — Mar 2025 [monthly]

    Active Not Recruiting PHASE3

  2. Sep 2024 — Dec 2024 [monthly]

    Active Not Recruiting PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE3

  4. Jun 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE3

  5. Apr 2024 — Jun 2024 [monthly]

    Active Not Recruiting PHASE3

  6. Jan 2024 — Apr 2024 [monthly]

    Active Not Recruiting PHASE3

  7. Oct 2023 — Jan 2024 [monthly]

    Active Not Recruiting PHASE3

  8. Jul 2023 — Oct 2023 [monthly]

    Active Not Recruiting PHASE3

  9. Jul 2022 — Jul 2023 [monthly]

    Active Not Recruiting PHASE3

  10. Apr 2022 — Jul 2022 [monthly]

    Active Not Recruiting PHASE3

  11. Dec 2021 — Apr 2022 [monthly]

    Active Not Recruiting PHASE3

  12. Sep 2021 — Dec 2021 [monthly]

    Active Not Recruiting PHASE3

  13. Jun 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE3

  14. Jan 2021 — Jun 2021 [monthly]

    Active Not Recruiting PHASE3

  15. Sep 2019 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  16. Apr 2019 — Sep 2019 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  17. Jun 2018 — Apr 2019 [monthly]

    Recruiting PHASE3

  18. Jun 2017 — Jun 2018 [monthly]

    Recruiting PHASE3

  19. Feb 2017 — Jun 2017 [monthly]

    Recruiting PHASE3

  20. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Acerta Pharma BV
Data source: Acerta Pharma BV

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Addington, New Zealand , Adelaide, Australia , Antwerp, Belgium , Aschaffenburg, Germany , Ashkelon, Israel , Athens, United States , Aviano, Italy , Badalona, Spain , Barrie, Canada , Bergamo, Italy and 133 more locations